# A Study on Safety and Efficacy of Two Doses of Topiramate as Monotherapy in the Treatment of Newly Diagnosed or Recurrent Epilepsy

> **NCT00231556** · PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 750 (actual)

## Conditions studied

- Epilepsy
- Seizures
- Epilepsies, Partial
- Epilepsy, Generalized
- Epilepsy, Tonic-Clonic

## Interventions

- **DRUG:** topiramate

## Key facts

- **NCT ID:** NCT00231556
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-07
- **Primary completion:** —
- **Final completion:** 2003-09
- **Target enrollment:** 750 (ACTUAL)
- **Last updated:** 2011-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00231556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00231556, "A Study on Safety and Efficacy of Two Doses of Topiramate as Monotherapy in the Treatment of Newly Diagnosed or Recurrent Epilepsy". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00231556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*